DAM
CTMX icon

Deltec Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Deltec Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,000
Closed -$129K – 161
2019
Q1 		$129K Buy
+12,000
New +$177K 0.03% 154

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deltec Asset Management's CTMX Position: Q2 2019 in Review

Deltec Asset Management sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 12,000 shares — an estimated $129K sold.

Deltec Asset Management first reported a position in CTMX in Q1 2019 and held it in 1 quarter. The position peaked at $129K in Q1 2019. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Deltec Asset Management reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Deltec Asset Management sold 12,000 CytomX Therapeutics shares in Q2 2019, an estimated $129K.
  • Deltec Asset Management first reported a position in CytomX Therapeutics in Q1 2019 and held it in 1 quarter.
  • Deltec Asset Management's CytomX Therapeutics position peaked at $129K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Deltec Asset Management's 13F filing for Q2 2019, filed 29 Jul 2019.